Table 4.

Secondary Outcome: Author Interpretation of Potential Reasons for Findings of Inconsistency with the FDA table of Inhibitors

Inhibitor	Classification per FDA Table of Inhibitors	Author Interpretation
Abiraterone	Weak	Unclear mechanism for inconsistent results
Celecoxib	Weak	Total daily doses ≤ 200 mg did not exhibit inhibition while 400 mg exhibited weak inhibition
Cimetidine	Weak & Moderate	Typically a weak inhibitor; only exhibited moderate inhibition with substrates affected by multiple pathways inhibited by cimetidine
Cinacalcet	Moderate	Typically a moderate inhibitor; multiple possibilities for inconsistent results (i.e., dose, steady state, and substrate sensitivity)
Clobazam	Weak	Always displayed weak inhibition although it was only studied with one substrate and one dosing strategy
Desvenlafaxine	Weak	Insignificant inhibition at clinically relevant doses
Duloxetine	Moderate	Unclear mechanism for inconsistent results
Escitalopram	Weak	All published evidence assessed supports the FDA classification as a weak inhibitor, although the FDA product label reports an AUC-fold increase that is at the lower limit of moderate inhibition
Fluvoxamine	Moderate	Weak inhibitor unless the substrate is affected by multiple pathways inhibited by fluvoxamine
Mirabegron	Moderate	Labeled dose exhibits moderate inhibition in NMs, but weak inhibition in populations that include IMs. Daily doses above the product labeling regardless of phenotype exhibit moderate inhibition.
Ritonavir	Weak	Weak inhibitor at typical doses unless the substrate is affected by multiple pathways inhibited by ritonavir
Sertraline	Weak	Weak inhibitor once sertraline reaches steady state

Concordance was defined as the inhibitor’s observed classification matched the classification per the FDA Table of Inhibitors.